As of November 6, 2026, Obsidian Therapeutics, Inc. is a publicly traded company (Nasdaq: OBX); its largest reported holder is RA Capital, with 9.7% on Schedule 13G of August 10, 2026, then Paradigm BioCapital Advisors LP (6.6%). The largest insider holding is Matthew Norkunas, a director, with 30,937 shares (0.05% of shares outstanding), per Form 3 of August 3, 2026 (Schedule 13G, August 10, 2026).
Is this your company?
About to sign with, pay or invest in Obsidian Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Obsidian Therapeutics, Inc. a real, registered company?
- Obsidian Therapeutics, Inc. files with the SEC under CIK 2130606 (its SEC filings).
- Its shares are listed under the ticker OBX on Nasdaq (SEC company record).
- business address in Cambridge, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Obsidian Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Paradigm BioCapital Advisors LP (filed 2026-10-05).
Who are Obsidian Therapeutics, Inc.'s owners and officers?
Obsidian Therapeutics, Inc.: business address in Cambridge, Massachusetts; industry Pharmaceutical Preparations (Schedule 13G, 2026-10-05).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-10-05 | Paradigm Biocapital Advisors LP | 6.6% |
| Schedule 13G, 2026-08-11 | Deep Track Capital, LP | 5.37% |
| Schedule 13G, 2026-08-10 | Novo Holdings A/S | 5.1% |
| Schedule 13G, 2026-08-10 | Ra Capital Management, L.P. | 9.7% |
| Schedule 13G, 2026-08-10 | Atlas Venture Fund X, L.P. | 4.3% |
Questions about who owns Obsidian Therapeutics, Inc.
Who owns Obsidian Therapeutics, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Obsidian Therapeutics, Inc.: Ra Capital Management, L.P. (9.7%, Schedule 13G, filed 2026-08-10), Paradigm Biocapital Advisors LP (6.6%, Schedule 13G, filed 2026-10-05), Deep Track Capital, LP (5.37%, Schedule 13G, filed 2026-08-11) and Novo Holdings A/S (5.1%, Schedule 13G, filed 2026-08-10).
Who are the largest shareholders of Obsidian Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Obsidian Therapeutics, Inc. on this page are Ra Capital Management, L.P. (9.7%), Paradigm Biocapital Advisors LP (6.6%) and Deep Track Capital, LP (5.37%).
When did Ra Capital Management, L.P. buy into Obsidian Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Ra Capital Management, L.P. on this page is the Schedule 13G, filed 2026-08-10, reporting 9.7%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Obsidian Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Obsidian Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Obsidian Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Obsidian Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 30,937 shares (0.05% of shares outstanding) (Form 3, 2026-08-03).
Shares outstanding: 61,772,876 as of 2026-08-10, from the company's latest SEC cover page.
How much has Obsidian Therapeutics, Inc. raised?
Latest IPO step: Obsidian Therapeutics, Inc. filed to go public (S-1, 2026-08-28).
IPO filings: S-1, 2026-08-28; ticker OBX on Nasdaq.
Acquisitions reported on Form 8-K, Item 2.01: completed an acquisition (2026-08-03).
Keep reading
More on Obsidian Therapeutics, Inc. and the records around it.
Obsidian Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
Companies that share a holder
- Atlas Venture Fund X, L.P. also filed stake reports on 5 other companies: Kymera Therapeutics, Inc. (Aug 2026), Q32 Bio Inc. (May 2026), GENERATION BIO CO. (May 2026)
- Novo Holdings A/S also filed stake reports on 11 other companies: Avalyn Pharma Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026), MAPLIGHT THERAPEUTICS, INC. (Jul 2026)
- Paradigm BioCapital Advisors LP also filed stake reports on 22 other companies: Spyre Therapeutics, Inc. (Oct 2026), Tyra Biosciences, Inc. (Sep 2026), Arcellx, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/obsidian-therapeutics